Gilead Sciences (GILD) CEO O'Day sold 30,881 shares for $5.33M at an average $172.57 under a 10b5-1 plan
CEO O'Day exercised 15,881 options at $72.34 and sold shares for about $5.3M under a 10b5-1 plan; direct holdings 551,683.
Insider transactions reported
Daniel Patrick O'Day (Chairman & CEO at Gilead Sciences Inc., GILD) reported that they sold 30,881 shares for $5.33M at an average $172.57, and acquired 15,881 shares at $72.34 between Oct 30, 2026 and Nov 2, 2026. After these transactions the filing shows 551,683 shares held directly.
- Reporting person
- O'Day Daniel Patrick
- Role
- Chairman & CEO
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Oct 30, 2026 | Exercise or conversion of a derivative (M) | Common Stock1 | +15,881 | $72.34 | $1.15M | 582,564 direct |
| Oct 30, 2026 | Open-market sale (S) | Common Stock1, 2 | -15,881 | $175.25 | $2.78M | 566,683 direct |
| Nov 2, 2026 | Open-market sale (S) | Common Stock1, 3, 4, ... | -15,000 | avg $169.74 | $2.55M | 551,683 direct |
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Oct 30, 2026 | Exercise or conversion of a derivative (M) | Non-qualified Stock Option (Right to Buy)On 15,881 Common Stock1, 8 | -15,881 | - | - | 240,739 direct |
Holdings before and after
- Common Stock: 566,683 to 551,683 direct
- Non-qualified Stock Option (Right to Buy): 256,620 to 240,739 direct
Footnotes from the filing
- 1. The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026.
- 2. Sale prices for the transactions reported range from $175.05 to $175.45. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
- 8. The stock options have a four-year vesting schedule. 25% of the stock options vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
Transaction codes in this filing
- Open-market sale:
- Code S marks a sale in the open market or a private deal. The insider received cash for these securities.
- Exercise or conversion of a derivative:
- Code M marks the exercise or conversion of an option or other derivative under an exempt plan.
FAQ
What did O'Day report in this GILD Form 4?
Daniel Patrick O'Day (Chairman & CEO at Gilead Sciences Inc., GILD) reported that they sold 30,881 shares for $5.33M at an average $172.57, and acquired 15,881 shares at $72.34 between Oct 30, 2026 and Nov 2, 2026. After these transactions the filing shows 551,683 shares held directly.
How many GILD shares does O'Day hold after this filing?
The filing shows 551,683 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
Was this GILD insider sale made under a 10b5-1 plan?
The filing's footnotes mention a Rule 10b5-1 trading plan. Such a plan sets the terms of future trades in advance.
What does transaction code S mean on an SEC Form 4?
Code S marks a sale in the open market or a private deal. The insider received cash for these securities.
Historical context for GILD
Across the 25 sessions after earlier GILD headlines, the stock closed higher 9 times and lower 16 times, with a median move of 1.1% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | GILD | SPY |
|---|---|---|---|
| Nov 2, 2026 | Gilead to Present Late-Breaking Clinical Data and Real-World Evidence at HIV Glasgowand 1 other headline that session | -0.2% | -0.5% |
| Oct 30, 2026 | Gilead Sciences Announces Third Quarter 2026 Financial Results | +3.1% | -1.8% |
| Oct 27, 2026 | Canadians Living with Primary Biliary Cholangitis (PBC) One Step Closer to New Treatment Option as Gilead Reaches Milestone National Agreement for LYVDELZI® (seladelpar) | +0.2% | +0.6% |
| Oct 23, 2026 | Gilead to Acquire Investigational Oral IL-23R Inhibitor HCXT-2001, Strengthening Its Inflammation Pipeline in IBD | -0.7% | -0.5% |
| Oct 22, 2026 | Gilead to Present New Data on Treatment Response and Long-Term Management of Rare Liver Diseases at The Liver Meeting® 2026 | +2.4% | -1.2% |
| Oct 19, 2026 | Gilead to Present New Data Across HIV and Emerging Antiviral Research at IDWeek 2026 | -2.0% | +0.4% |
Earlier insider filings at GILD
- Oct 16, 2026Chief Financial Officer Dickinson Andrew D sold $468,660 worth of shares (3,000 units at $156.22) as part of a pre-agreed trading plan (SEC Form 4)
- Oct 16, 2026Chief Comm & Corp Aff Officer Mercier Johanna sold $468,660 worth of shares (3,000 units at $156.22) as part of a pre-agreed trading plan (SEC Form 4)
- Oct 2, 2026Chairman & CEO O'Day Daniel Patrick sold $2,218,508 worth of shares (15,000 units at $147.90) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 566,683 units (SEC Form 4)
- Sep 23, 2026SVP, Controllership Burkhart Erin converted options into 2,223 shares and covered exercise/tax liability with 768 shares (SEC Form 4)
- Sep 16, 2026Chief Financial Officer Dickinson Andrew D sold $435,870 worth of shares (3,000 units at $145.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 164,096 units (SEC Form 4)
Keep researching GILD
- GILD insider tradesEvery buy and sale reported by Gilead Sciences Inc. officers, directors and large holders.
- What is Form 4?The SEC filing that reports a change in an insider's holdings, such as a purchase, sale, option exercise or grant, generally within two business days.
- Form 4 explainedForm 4 is the SEC filing that discloses when officers, directors and 10% owners buy or sell company stock, due within 2 business days. Learn every key field and code.
- Insider trading trackerThe latest insider buys and sales across every stock.
- GILD earnings historyPast Gilead Sciences Inc. earnings releases, newest first.
- GILD financial statementsRevenue, profit, cash flow and balance sheet from Gilead Sciences Inc.'s SEC filings.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 1992
Follow GILD and get a push notification the moment its next story breaks.